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Osteoarthritis is an age-related degenerative musculoskeletal disease characterised by 
loss of articular cartilage, synovitis and subchondral bone sclerosis. Osteoarthritis 
pathogenesis is yet to be fully elucidated with no osteoarthritis specific biomarkers in 
clinical use. Ex-vivo equine cartilage explants (n=5) were incubated in TNF-α/IL-1β 
supplemented culture media for 8 days, with media removed and replaced at 2, 5 and 8 
days. Acetonitrile metabolite extractions of 8 day cartilage explants and media samples at 
all time points underwent 1D 1H nuclear magnetic resonance metabolomic analysis with 
media samples also undergoing mass spectrometry proteomic analysis. Within the 
cartilage, glucose and lysine were elevated following TNF-α/IL-1β treatment whilst 
adenosine, alanine, betaine, creatine, myo-inositol and uridine decreased. Within the 
culture media, four, four and six differentially abundant metabolites and 154, 138 and 72 
differentially abundant proteins were identified at 1-2 days, 3-5 days and 6-8 days 
respectively, including reduced alanine and increased isoleucine, enolase 1, vimentin and 
lamin A/C following treatment. Nine potential novel osteoarthritis neopeptides were 
elevated in treated media. Implicated pathways were dominated by those involved in 
cellular movement. Our innovative study has provided insightful information on early 
osteoarthritis pathogenesis, enabling potential translation for clinical markers and possible 
new therapeutic targets. 
 





Osteoarthritis (OA) is an age-related degenerative musculoskeletal disease characterised 
by loss of articular cartilage, synovial membrane dysfunction, abnormal bone proliferation, 
subchondral bone sclerosis and altered biochemical and biomechanical properties 1,2. For 
horses in the UK, OA is one of the leading welfare issues, resulting in substantial morbidity 
and mortality 3,4. It is estimated that OA accounts for 60% of lameness seen in horses 5. 
Within OA, extracellular matrix (ECM) degradation is driven by multiple matrix 
metalloproteinases (MMPs) and a disintegrin and metalloproteinases with thrombospondin 
motifs (ADAMTSs) 6. However, the underlying pathogenesis of OA is yet to be fully 
elucidated with no disease-modifying treatments currently available 7,8. Whilst a number of 
putative biomarkers have been identified for OA diagnosis in the horse, none are currently 
used within clinical practice 9. Presently, equine OA is predominantly diagnosed through 
diagnostic imaging and clinical examination. However, due to the slow onset of the 
condition, this often leads to substantial pathology of the joint, particularly to articular 
cartilage prior to diagnosis 10. There is therefore a need to develop diagnostic tests which 
are sensitive and specific to the early stages of OA, which are repeatable and 
reproducible, as well as gaining a greater understanding of the underlying pathogenesis 
11,12. Early detection of OA could enable timely management interventions which could 
potentially slow the progression of the disease. 
Tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) are both pro-inflammatory 
cytokines which are central in OA pathogenesis 13. TNF-α and IL-1β are secreted by 
mononuclear cells, synoviocytes and articular cartilage and upregulate gene expression of 
MMPs, ADAMTS-4 and ADAMTS-5, leading to significant ECM degradation 14–16. 
Elevations in TNF-α and IL-1β are regularly identified within OA synovial fluid, including 
that of horses 17–19. TNF-α and IL-1β have therefore become established experimental 
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treatments for modelling OA pathology within in vitro and ex-vivo studies, having been 
used both independently and as a combined treatment 20–26. 
Proteomics is the systematic, large scale study of proteins within biological systems to 
assess quantities, isoforms, modifications, structure and function 27. Previous studies have 
undertaken mass spectrometry (MS) based proteomics using TNF-α and IL-1β OA models 
for secretome analysis of chondrocytes in vitro and ex-vivo cartilage explants 20–22,25. 
Results from these studies included increased media levels of MMPs, cartilage oligomeric 
matrix protein (COMP), aggrecan and collagen VI. 
During OA pathology, disease-associated peptide fragments (neopeptides) are generated 
from cartilage breakdown due to increased enzymatic activity/abundance of MMPs, 
ADAMTSs, cathepsins and serine proteases 28–30. MS analysis of these neopeptides can 
then be applied to identify potential early OA biomarkers 31. Previously a murine 32 amino 
acid peptide fragment, generated through increased activity of MMP and ADAMTS-4/5 and 
subsequent aggrecan degradation, was found to drive OA pain via Toll-like receptor 2 32. 
Neopeptide targeting therefore has the potential to provide a localised analgesic at the site 
of joint degeneration 31. Numerous equine OA studies investigating both synovial fluid (SF) 
and cartilage have identified potential neopeptides of interest 28,33–35.  Development of 
antibodies targeted to OA specific neopeptides would provide the ability to monitor 
cartilage degeneration, assess therapeutic response and potentially provide future novel 
therapeutic targets 31,36.  
Metabolomics uses a systematic methodology to comprehensively identify and quantify the 
metabolic profiles of biological samples 37. 1H Nuclear magnetic resonance (NMR) 
metabolomics analysis provides a high level of technical reproducibility with a minimal 
level of sample preparation 38. 1H NMR analysis has previously been used to investigate 
OA in the SF of humans, horses, pigs and dogs 9,39–45. Synovial metabolites alanine, 
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choline, creatine and glucose have been identified as differentially abundant in OA across 
multiple studies and species 9,39,41–44. NMR techniques have also previously been used to 
characterise cartilage with high resolution magical angle spinning (HRMAS) NMR utilised 
to assess enzymatic degradation of bovine cartilage 46–48. A guinea pig OA model using 
HRMAS NMR identified elevations in methylene resonances associated with chondrocyte 
membrane lipids and an increase in mobile methyl groups of collagen 49. Another HRMAS 
NMR study of human OA cartilage identified a reduction in alanine, choline, glycine, lactate 
methyne and N-acetyl compared to healthy control cartilage 50. However, no NMR studies 
to date have investigated the metabolic profile of culture media following the incubation of 
ex-vivo cartilage within an OA model. 
This is the first study to carry out 1H NMR metabolomic analysis of extracted cartilage 
metabolites and also to undertake 1H NMR analysis of culture media using the TNF-α/IL-
1β ex-vivo OA cartilage model. Additionally, this is also the first study to use a multi ‘omics’ 
approach to simultaneously investigate the metabolomic profile of ex-vivo cartilage and 
metabolomic/proteomic profiles of culture media using this OA model and conduct an 
integrated pathway analysis. It was hypothesised that following TNF-α/IL-1β treatment of 
ex-vivo equine cartilage, 1H NMR metabolomic and MS proteomic platforms would identify 
a panel of cartilage metabolites which were able to differentiate control from treated 
cartilage and a panel of metabolites, proteins and neopeptides within the associated 





Equine Ex-Vivo Cartilage Collection 
Full thickness cartilage was removed from all articular surfaces within five separate 
metacarpophalangeal joints of five nine-year-old mares of unknown breed within 24 hr of 
slaughter at a commercial abattoir (F Drury and Sons, Swindon, UK). Cartilage samples 
were collected as a by-product of the agricultural industry. The Animals (Scientific 
Procedures) Act 1986, Schedule 2, does not define collection from these sources as 
scientific procedures and ethical approval was therefore not required. Cartilage collected 
from all joints was considered macroscopically normal with a score of 0 according to the 
OARSI histopathology initiative scoring system for horses 51 (Figure S1). Cartilage was 
washed in complete media containing Dulbecco’s modified Eagle’s medium (DMEM, 
31885-023, Life Technologies, Paisley, UK) supplemented with 10% (v/v) foetal calf serum 
(FCS, Life Technologies), 5 μg/ml Amphotericin B (Life Technologies), 100 U/ml 
Streptomycin and 100 U/ml Penicillin (Sigma-Aldrich, Gillingham, UK) (Figure S2). 
Cartilage was dissected into 3 mm2 sections and divided into two for each donor (control 
and treatment wells) on a twelve well plate (Greiner Bio-One Ltd., Stonehouse, UK). 
Explants were incubated for 24 hr in complete media within a humidified atmosphere of 
5% (v/v) CO2 at 37°C. Culture media was removed, explants washed in phosphate 
buffered saline (PBS, Sigma-Aldrich) and replaced with serum free media (control) or 
serum free media supplemented with 10 ng/ml TNF-α (PeproTech EC Ltd., London, UK) 
and 10 ng/ml IL-1β (R&D Systems Inc., Minneapolis, Minnesota, USA) (treatment). After 
48 hr, media was removed, centrifuged at 13,000g, 4°C for 10 min, supernatant removed 
and ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail (Roche, 
Lewes, UK) added to cell-free media. Supernatant was then snap frozen in liquid nitrogen 
and stored at -80°C. Cartilage was washed in PBS and control/treatment culture media 
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replaced as appropriate. Media collection was repeated at five and eight days. After day 
eight, cartilage was washed in PBS, weighed, snap frozen in liquid nitrogen and stored at -
80°C. 
NMR Metabolomics 
Cartilage - Metabolite Extraction 
Equal masses of cultured cartilage explants (in addition to three macroscopically normal 
equine cartilage samples, each divided into three to assess metabolite extraction 
reproducibility) were thawed out over ice and added to 500 µl of 50:50 (v/v) ice cold 
acetonitrile (ThermoFisher Scientific, Massachusetts, USA):dd 1H2O and incubated on ice 
for 10 min. Samples were then sonicated using a microtip sonicator at 50 KHz and 10 nm 
amplitude in an ice-bath for three 30 s periods, interspersed with 30 s rests (that ensured 
extraction mixture temperature did not exceed 15°C). The extraction mixture was then 
vortexed for 1 min, centrifuged at 12,000g for 10 min at 4°C, supernatant transferred 
before being snap frozen in liquid nitrogen, lyophilised and stored at -80°C 37. 
Cartilage - NMR Sample Preparation 
Each lyophilised sample was dissolved through the addition of 200 µl of 100 µM PO43- pH 
7.4 buffer (Na2HPO4, VWR International Ltd., Radnor, Pennsylvania, USA and NaH2PO4, 
Sigma-Aldrich), containing 100 µM d4 trimethylsilyl propionate (TSP, Sigma-Aldrich) and 
1.2 µM sodium azide (NaN3, Sigma-Aldrich) in 99.9% deuterium oxide (2H2O, Sigma-
Aldrich). Samples were vortexed for 1 min, centrifuged at 12,000g for 2 min, 190 µl of 




Culture Media - NMR Sample Preparation 
Culture media was thawed over ice and centrifuged for 5 min at 21,000g and 4°C. 150 µl 
of thawed culture media was diluted to a final volume containing 50% (v/v) culture media, 
40% (v/v) dd 1H2O, 10% 2H2O and 0.0025% (v/v) NaN3, within an overall concentration of 
500 mM PO43- pH 7.4 buffer. Samples were vortexed for 1 min, centrifuged at 13,000g for 
2 min at 4°C, 250 µl supernatant removed and transferred to 3 mm outer diameter NMR 
tubes using a glass pipette. 
NMR Acquisition 
For each individual sample, 1D 1H NMR spectra, with the application of a Carr-Purcell-
Meiboom-Gill (CPMG) filter to attenuate macromolecule (e.g. proteins) signals, were 
acquired using the standard vendor pulse sequence cpmgpr1d on a 700 MHz NMR Bruker 
Avance III HD spectrometer with associated TCI cryoprobe and chilled Sample-Jet 
autosampler. All spectra were acquired at 25°C, with a 4 s interscan delay, 256 transients 
for cartilage spectra and 128 transients for media spectra, with a spectral width of 15 ppm. 
Topsin 3.1 and IconNMR 4.6.7 software programmes were used for acquisition and 
processing undertaking automated phasing, baseline correction and a standard vendor 
processing routine (exponential window function with 0.3 Hz line broadening). In addition 
to all cartilage extract and culture media samples, protease inhibitor cocktail and treatment 
cytokines TNF-α and IL-1β were also analysed separately to evaluate their metabolite 
profiles. 
Metabolite Annotation and Identification 
All acquired spectra were assessed to determine whether they met minimum reporting 
standards (as outlined by the Metabolomics Society) prior to inclusion for statistical 
analysis 52. These included appropriate water suppression, flat spectral baseline and 
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consistent linewidths. Metabolite annotations and relative abundances were carried out 
using Chenomx NMR Suite 8.2 (330-mammalian metabolite library). When possible, 
metabolite identifications were confirmed using 1D 1H NMR in-house spectral libraries of 
metabolite standards. All raw 1D 1H NMR spectra, together with annotated metabolite 
HMDB IDs and annotation level, are available within the EMBL-EBI MetaboLights 
repository (www.ebi.ac.uk/metabolights/MTBLS1495) 53. Quantile plots of 1D 1H NMR 
spectra are shown in Figure S3. 
Culture Media Proteomics 
Protein Assay and StrataCleanTM Resin Processing 
Culture media was thawed over ice and centrifuged for 5 min at 21,000g and 4°C. Media 
sample concentrations were determined using a Pierce® 660 nm protein assay (Thermo 
Scientific, Waltham, Massachusetts, USA). 50 µg of protein for each sample was diluted 
with dd H2O, producing a final volume of 1 ml. StrataCleanTM resin (10 µl) (Agilent, Santa 
Clara, California, USA) was added to each sample, rotated for 15 min, centrifuged at 400g 
for 1 min and the supernatant removed and discarded. Samples were then washed 
through the addition of 1 ml of ddH2O, vortexed for 1 min, centrifuged at 400g for 1 min 
and the supernatant removed and discarded. The wash step was repeated two further 
times. 
Protein Digestion 
160 µl of 25 mM ammonium bicarbonate (Fluka Chemicals Ltd., Gillingham, UK) 
containing 0.05% (w/v) RapiGest (Waters, Elstree, Hertfordshire, UK) was added to each 
sample and heated at 80°C for 10 min. DL-Dithiothreitol (Sigma-Aldrich) was added to 
produce a final concentration of 3 mM, incubated at 60°C for 10 min then iodoacetamide 
(Sigma-Aldrich) added (9 mM final concentration) and incubated at room temperature in 
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the dark for 30 min. 2 µg of proteomics grade trypsin (Sigma-Aldrich) was added to each 
sample, rotated at 37°C for 16 hr and trypsin treatment then repeated for a 2 hr incubation. 
Samples were centrifuged at 1,000g for 1 min, digest removed, trifluoroacetic acid (TFA, 
Sigma-Aldrich) added (0.5% (v/v) final concentration) and rotated at 37°C for 30 min. 
Finally, digests were centrifuged at 13,000g and 4°C for 15 min and the supernatant 
removed and stored at 4°C. 
Label Free LC-MS/MS 
All media digests were randomised and individually analysed using LC-MS/MS on an 
UltiMate 3000 Nano LC System (Dionex/Thermo Scientific) coupled to a Q ExactiveTM 
Quadrupole-Orbitrap instrument (Thermo Scientific). Full LC-MS/MS instrument methods 
are described in the supporting information. Tryptic peptides, equivalent to 250 ng of 
protein, were loaded onto the column and run over a 1 hr gradient, interspersed with 30 
min blanks (97% (v/v) high performance liquid chromatography grade H20 (VWR 
International), 2.9% acetonitrile (Thermo Scientific) and 0.1% TFA. In addition to individual 
time points, pooled samples for control and treatment groups were also analysed to 
investigate differences in the overall secretome. The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium via the PRIDE partner 
repository with the dataset identifier PXD017153 and 10.6019/PXD017153 54. 
Representative ion chromatograms are shown in Figure S4. 
LC-MS/MS spectra processing and protein identification 
Spectral alignment, peak picking, total protein abundance normalisation and 
peptide/protein quantification were undertaken using Progenesis™ QI 2.0 (Nonlinear 
Dynamics, Waters). The exported top ten spectra for each feature were then searched 
against the Equus caballus database for peptide and protein identification using PEAKS® 
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Studio 8.5 (Bioinformatics Solutions Inc., Waterloo, Ontario, Canada) software. Search 
parameters were: precursor mass error tolerance, 10.0 ppm; fragment mass error 
tolerance, 0.01 Da; precursor mass search type, monoisotopic; enzyme, trypsin; maximum 
missed cleavages, 1; non-specific cleavage, none; fixed modifications, 
carbamidomethylation; variable modifications, oxidation or hydroxylation and oxidation 
(methionine). A filter of a minimum of 2 unique peptides was set for protein identification 
and quantitation with a false discovery rate (FDR) of 1%.  
1D SDS PAGE 
Media samples for each donor were combined for all time points and analysed via one 
dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis (1D SDS PAGE). 
1 μg of each sample was added to Laemmli loading buffer Novex™ (Thermo Scientific) 
producing a final concentration of 15% glycerine, 2.5% SDS, 2.5% Tris (hydroxymethyl) 
aminomethane, 2.5% HCL and 4% β-mercaptoethanol at pH 6.8 and heated at 95°C for 5 
min. Samples were loaded onto a 4-12% Bis-Tris polyacrylamide electrophoresis gel 
(NuPAGE™ Novex™, Thermo Scientific) and protein separation carried out at 200 V for 
30 min at room temperature. Protein bands were visualised via silver staining (Thermo 
Scientific) following manufacturer instructions. Gel images were converted to 8 bit grey 
scale and protein band intensities analysed using densitometry with the software Image J 
(NIH, Bethesda, Maryland). 
Semi-Tryptic Peptide Identification 
To identify potential neopeptides a ‘semi-tryptic’ search was undertaken. The same 
PEAKS® search parameters were used as for protein identification, with the exception that 
‘non-specific cleavage’ was altered from ‘none’ to ‘one’. The ‘peptide ion measurements’ 




Cartilage metabolite profiles were normalised using probabilistic quotient normalisation 
(PQN) 55. Media metabolites were normalised to TSP concentration and protein profiles 
normalised to total ion current (TIC). Prior to multivariate analysis, metabolite and protein 
profiles were Pareto scaled 56. MetaboAnalyst 3.5 (http://www.metaboanalyst.ca) was used 
to produce principal component analysis (PCA) plots and provide PC1 (principal 
component 1) loadings magnitude values. t-tests were carried out using MetaboAnalyst 
3.5 (protein and metabolite abundances) and the neopeptide analyser (neopeptides) with p 
< 0.05 (and a fold change of > 2 for proteins) considered statistically significant. The 
Benjamini-Hochberg false discovery rate method was applied for correction of multiple 
testing 57. The SPSS 24 software package was used to produce all box plots and PC1 
loadings magnitude graphs. 
Pathway Analysis 
Owing to the minimal annotation of the equine genome, equine proteins and metabolites 
were converted to their human orthologues prior to pathway analysis. Functional analyses 
of differentially expressed proteins and metabolites within culture media were undertaken 
to evaluate the differences due to the application of TNF-α and IL-1β at all three time 
points. Networks, functional analyses and canonical pathways were generated through the 
use of Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood City, California, 
USA) on the list of differentially expressed proteins and metabolites, p < 0.05 and ± 2 fold 
regulation. Protein and metabolite symbols were used as identifiers and the Ingenuity 
Knowledge Base gene used as a reference for pathway analysis. For network generation, 
a dataset containing combined protein and metabolite identifiers and corresponding 
expression values was uploaded into the application. These molecules were overlaid onto 
a global molecular network contained in the Ingenuity Knowledge Base. Networks of 
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network-eligible molecules were then algorithmically generated based on their 
connectivity. The functional analysis identified the biological functions and diseases that 
were most significant to the dataset. A right-tailed Fisher’s exact test was used to calculate 
p values. Canonical pathways analysis identified the pathways from the IPA library of 
canonical pathways that were most significant to the datasets. 
Results 
NMR Metabolomics 
Protease inhibitor cocktail, TNF-α and IL-1β metabolite profiles 
Protease inhibitor cocktail was found to have high levels of mannitol and thus this 
metabolite was removed from all analyses. Within the spectral profiles of TNF-α and IL-1β 
acquired separately, the metabolites acetate, acetone, ethanol, formate, lactate, methanol 
and succinate were identified. These metabolites were therefore also removed from further 
analyses. 
Analysis of Cartilage Metabolites 
Acetonitrile metabolite extraction was identified to be highly reproducible with technical 
replicates clustering within a PCA plot for three separate macroscopically normal cartilage 
samples (Figure S5). In total 35 metabolites were identified within equine cartilage (Table 
1). Of these, following the removal of metabolites previously mentioned, eight were 
identified as being differentially abundant between control and treatment groups (Figure 1). 
Glucose and lysine levels were elevated following TNF-α/IL-1β treatment whilst adenosine, 
alanine, betaine, creatine, myo-inositol and uridine levels decreased. PCA identified that 
metabolite profiles separated into two distinct clusters, separating control and treatment 
groups (Figure 2a). Of the top 25 PC1 loadings, myo-inositol was found to be the most 
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influential cartilage metabolite in separating control and treated samples, followed by 
glucose, betaine and alanine (Figure 2b). 
 
Table 1. Metabolites annotated within cartilage and culture media using Chenomx. 
Metabolites additionally identified using a 1D 1H NMR in-house library have been assigned 













HMDB00695 2-Oxoisocaproate     Y MS Level 2 
HMDB00491 3-Methyl-2-oxovalerate     Y MS Level 2 
HMDB31645 Acetamide Y MS Level 2     
HMDB00042 Acetate * Y MS Level 1 Y MS Level 1 
HMDB01659 Acetone *     Y MS Level 2 
HMDB00050 Adenosine Y MS Level 2     
HMDB00517 Arginine     Y MS Level 2 
HMDB00191 Aspartate Y MS Level 1     
HMDB00043 Betaine Y MS Level 1     
HMDB00097 Choline     Y MS Level 1 
HMDB00094 Citrate Y MS Level 1 Y MS Level 1 
HMDB00064 Creatine Y MS Level 1     
HMDB00562 Creatinine Y MS Level 1 Y MS Level 1 
HMDB00192 Cystine     Y MS Level 2 
HMDB00122 D-Glucose Y MS Level 1     
HMDB04983 Dimethyl sulfone Y MS Level 2     
HMDB00108 Ethanol *     Y MS Level 1 
HMDB00142 Formate * Y MS Level 2 Y MS Level 2 
HMDB00123 Glycine Y MS Level 1 Y MS Level 1 
HMDB00870 Histamine     Y MS Level 2 
HMDB00172 Isoleucine Y MS Level 1 Y MS Level 1 
HMDB00863 Isopropanol *     Y MS Level 2 
HMDB00190 Lactate * Y MS Level 1 Y MS Level 1 
HMDB00161 L-Alanine Y MS Level 1 Y MS Level 1 
HMDB00062 L-Carnitine     Y MS Level 2 
HMDB00148 L-Glutamate Y MS Level 1 Y MS Level 1 
HMDB00641 L-Glutamine Y MS Level 1 Y MS Level 1 
HMDB00177 L-Histidine     Y MS Level 1 
HMDB00687 L-Leucine Y MS Level 1 Y MS Level 1 
HMDB00159 L-Phenylalanine Y MS Level 1 Y MS Level 1 
HMDB00167 L-Threonine Y MS Level 2 Y MS Level 2 
HMDB00158 L-Tyrosine Y MS Level 1 Y MS Level 1 
HMDB00883 L-Valine Y MS Level 1 Y MS Level 1 
HMDB00182 Lysine Y MS Level 1 Y MS Level 1 
HMDB00765 Mannitol *     Y MS Level 1 
HMDB01875 Methanol *     Y MS Level 2 
HMDB00696 Methionine Y MS Level 1 Y MS Level 1 
HMDB01844 Methylsuccinate Y MS Level 2     
HMDB00211 myo-Inositol Y MS Level 1     
HMDB03269 Nicotinurate Y MS Level 2 Y MS Level 2 
HMDB00895 O-Acetylcholine Y MS Level 2     
HMDB00210 Pantothenate Y MS Level 2   
HMDB00267 Pyroglutamate     Y MS Level 2 
HMDB00243 Pyruvate Y MS Level 1     
HMDB00086 
sn-Glycero-3-
phosphocholine Y MS Level 2     






Y = Yes; * = Metabolite removed from subsequent analyses
HMDB00929 Tryptophan     Y MS Level 1 
HMDB00300 Uracil Y MS Level 2     
HMDB00296 Uridine Y MS Level 1     
HMDB00001 τ-Methylhistidine Y MS Level 2     
17 
 
   
Figure 1. Boxplots of differentially abundant extracted ex-vivo equine cartilage metabolites for control (n=5) and following TNF-α/IL-1β 




Figure 2. PCA (A, C and E), and PC1 RMS (Principal component 1 root mean square) 
values (B, D and F) for the 25 components with the highest magnitude for metabolites and 
proteins present in ex-vivo equine cartilage and culture media for combined time points 
over 8 days, comparing controls (red, n=5) to TNF-α/IL-1β treatment (green, n=5). RMS: 







Analysis of Media Metabolites 
Spectral quality control via metabolomics standards initiative identified two samples that 
failed due to salt precipitation and as such were removed from further analyses 52,59. 
Following metabolite identification and quantification, one sample was identified as an 
outlier and subsequently removed from statistical analyses. Isopropanol was identified 
within all media samples. As this was considered a likely contaminant during cartilage 
culture, together with metabolites previously mentioned, isopropanol was also removed 
from all analyses. In total, 34 metabolites were identified within the culture media (Table 
1). Time points were analysed separately with four, four and six metabolites identified as 
being differentially abundant between control and treatment groups for 1-2 day, 3-5 day 
and 6-8 day time points respectively (Figure 3). Choline levels were increased in treated 
samples compared to controls for all three time points whilst alanine and citrate levels 
decreased. At 3-5 days glutamate levels were reduced following treatment. At 6-8 days, 
following treatment, arginine and isoleucine levels were elevated whilst 2-oxoisocaproate 
and 3-methyl-2-oxovalerate levels were found to decrease. PCA of combined and 
separated time points identified clear separation between the metabolite profiles of control 
and treated media samples (Figure 2c and Figure 4a, b and c). Metabolite loadings for 















Figure 3. Boxplots of differentially abundant metabolites within the culture media following incubation of ex-vivo equine cartilage for 
control samples (C, red) and following TNF-α/IL-1β treatment (T, green), at 0-2, 3-5 and 6-8 days (d). Metabolite abundances shown as 














Figure 4. Principal component analysis (PCA) plots of media metabolite (A-C) and protein 
(D-F) profiles at 0-2, 3-5 and 6-8 days for controls (green, n=5) and TNF-α/IL-1β treatment 
(red, n=5) of ex-vivo equine cartilage.  
 
LC-MS/MS Proteomics 
Analysis of Media Proteins 
In total, 303 proteins were identified within analysed culture media samples (Table S1). 
When time points were analysed separately, 154, 138 and 72 proteins were identified as 
being differentially abundant, with > 2 fold change, between control and treatment groups 
for 1-2 day, 3-5 day and 6-8 day time points respectively. PCA analysis of combined 
protein profiles identified groups were primarily separated by elevated COMP and 
decreased fibronectin following treatment (Figure 2e and f). PCA multivariate analysis also 
identified clear discrimination between control and treatment groups at all three time points 





magnitudes corresponding to individual proteins were identified (Figure S6). Box plots in 
Figure 5 represent proteins which were found to be represented within the top 25 PC1 
loadings magnitudes at all three time points (coagulation factor XIII A chain, COMP, 
enolase 1, Lamin A/C and MMP-3) and extracellular matrix related proteins of interest 
represented at 2/3 time points (collagen type VI α 2 chain, collagen type X α 1 chain, 
fibromodulin, fibronectin, matrix Gla protein, MMP1 and vimentin). Coagulation factor XIII 
A chain, enolase 1 and lamin A/C were elevated at all three time points following 
treatment. MMP-1 and MMP-3 levels were found to be statistically elevated at 0-2 days 
only. Fibromodulin and vimentin levels were increased following treatment at both 0-2 days 
and 3-5 day time points whilst COMP levels increased at 0-2 days and 6-8 days. Collagen 
type VI α 2 chain and matrix Gla protein levels decreased following treatment at 3-5 days 
and 6-8 days whilst collagen type X α 1 chain and fibronectin levels statistically decreased 
at 6-8 days alone. 
Silver stain analysis of the media profiles for combined time points identified two protein 
bands which were decreased in abundance following TNF-α/IL-1β treatment, with 














Figure 5. Boxplots of differentially abundant proteins within the culture media following incubation of ex-vivo equine cartilage for control 
samples (C, red) and following TNF-α/IL-1β treatment (T, green), at 0-2, 3-5 and 6-8 days (d). Protein abundances shown as relative 






PCA of all identified semi-tryptic peptides within combined control and combined treated 
samples identified far less variation within the treatment group (Figure 6). This was also 
identified for all time points analysed individually (Figure S8). In total, nine potential novel 
OA neopeptides were identified which were elevated in treated media samples (Table 2). 
These included semi-tryptic peptides of extracellular matrix proteins aggrecan, cartilage 








Figure 6. Principal component analysis (PCA) of semi-tryptic peptide profiles within culture 
media of control (red, n=5) and TNF-α/IL-1β treated (green, n=5) ex-vivo equine cartilage. 
Time points pooled for each individual donor. 
 
Table 2. Potential Osteoarthritis Neopeptides. Semi-tryptic peptides of extracellular 
matrix related and unknown proteins, identified within culture media, with an increased 



























F7C2J3 AIGVPQPYLNK N L 2.2 1.83E-
04 
Unknown N/A NGPTESTFSTSWK C G 5.4 2.24E-
04 
Unknown N/A LVIIR N K 4.9 3.05E-
04 
Vimentin F7B5C4 RQVDQLTNDK L A 2.7 4.09E-
04 
Combined Unknown N/A AFDQLR H N 6.4 3.05E-
04 
Collagen 
Type VI α 2 
Chain 
F7CGV8 KQNVVPTVVAV R G 6.5 3.85E-
04 
Unknown N/A DGAFLLR E Q 11.7 4.10E-
04 




Pathways implicated within the model at time points 0-2 days and 3-5 days following TNF-
α/IL-1β treatment were largely dominated by those involved in cellular movement (Figure 
S9). These included the upregulation of the canonical pathways actin cytoskeleton 
signalling, RhoA (Ras homologue gene family A) signalling and signalling by Rho family 
GTPases at both time points and the upregulation of actin-based motility by Rho at 0-2 
days (Figure 7). Network analysis of cellular movement, migration and invasion at 0-2 days 
identified key contributors to these pathways to include both metabolites and proteins; 
increased levels of L-glutamate, vimentin, coagulation factor XIII A chain, fibromodulin, 
lamin A/C and enolase 1 and reduced levels of fibrillin 1, tissue inhibitor of 
metalloproteinases 2 and collagen type XI alpha 1 chain following treatment (Figure S10). 
Glycolysis was also identified as being upregulated at both 0-2 days and 3-5 days. For 6-8 
days, pathway directionality was unable to be obtained for any of the significant pathways 
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identified. Alanine degradation and biosynthesis pathways were identified as significant for 
both 3-5 day and 6-8 day time points. 
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Figure 7. Altered canonical pathways associated with differentially abundant metabolites and proteins within culture media at (A) 0-2 
days, (B) 3-5 days and (C) 6-8 days following TNF-α/IL-1β treatment of ex-vivo equine cartilage explants. Canonical pathway significance 
was calculated using a right-sided Fisher's exact test and represented by the associated bars. The highest values represent canonical 
pathways which are least likely to have been identified due to random chance. Blue represents downregulated canonical pathways and 





In this study, TNF-α/IL-1β treatment of ex-vivo equine cartilage explants was used to 
model early OA to gain a greater understanding of OA pathogenesis and identify potential 
OA markers. 1H NMR metabolomic and LC-MS/MS proteomic analysis of culture media at 
0-2, 3-5 and 6-8 days was undertaken. In addition, 1H NMR metabolomic analysis of 
acetonitrile extracted cartilage metabolites (following 8 days incubation) was also carried 
out. 
Within culture media, following TNF-α/IL-1β treatment, elevations in endopeptidases MMP-
1 and MMP-3 at 0-2 days, with a similar trend at both other time points, were identified as 
expected 60. Elevated MMP-1 activity has previously been identified within equine OA SF 
with general MMP activity also found to be correlated to severity of cartilage damage 61,62. 
Also, as previously reported, elevations in the non-collagenous ECM protein COMP were 
also identified within the TNF-α/IL-1β equine OA model, with COMP considered a marker 
of cartilage breakdown 63,64. Clinically, elevated COMP levels have been identified within 
human OA SF, although within equine OA, one study identified reduced levels with COMP 
levels being unable to stage the disease 65,66. Fibronectin was identified as a key 
discriminator between control and treatment groups with reduced secreted fibronectin 
identified within the media following TNF-α/IL-1β treatment. Additionally, a protein band of 
molecular weight 160-260 kDa was identified as reduced in treated media compared to 
control samples via 1D SDS PAGE which may be representing fibronectin (250 kDa), 
although further techniques, i.e. Western blotting or MS/MS analysis of an in-gel tryptic 
digest, are required to confirm this 67,68. However, elevated levels of fibronectin have 
previously been identified within OA SF with fibronectin found to localise at sites of 
cartilage degeneration and subsequently secreted into the ECM by equine chondrocytes 
69,70. The reasons for this possible discrepancy in results between this study and previous 
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studies is currently not known and requires further investigation. It may be that within this 
study fibronectin has undergone post translational modifications following treatment which 
may not have been identified via the PEAKS® identification algorithm or resulted in ions 
which subsequently did not ‘fly’ well during MS analysis and thus were subsequently not 
identified as peptides. 
Our study benefitted by integrated pathway analysis of metabolites and proteins. Pathways 
implicated within this study were dominated by the upregulation of cellular movement 
pathways, particularly within the earlier stages of the OA model, including actin 
cytoskeleton signalling, signalling by Rho GTPases and RhoA signalling. The actin 
cytoskeleton is known to be regulated by Rho GTPase upstream regulators, with RhoA 
having been identified as having an important role in the regulation of cytoskeletal 
structure and focal adhesion maturation 71,72. The RhoA/ROCK (Rho-associated kinase) 
pathway has previously been established as having a critical function within the regulation 
of chondrocyte proliferation and differentiation, suppressing chondrogenesis by decreasing 
the expression of the chondrocyte transcription factor Sox9 72,73. Targeting this pathway 
may therefore provide a critical role in the development of cartilage tissue constructs, 
which are clinically translatable, to treat OA 74. Additionally, with an increasing body of 
evidence implicating the RhoA/ROCK pathway within OA development, this pathway is 
currently being investigated as a potentially novel therapeutic target within the patient’s 
own cartilage 75. Therefore, with activation of these pathways identified within this ex-vivo 
cartilage model of early OA, interrogating combined changes in the metabolome and 
proteome within this model may have a beneficial role in testing responses of novel 
therapeutics on the actin cytoskeleton/Rho GTPase pathways. 
Following TNF-α/IL-1β treatment, elevations of glucose within the cartilage were identified. 
This is supported by a previous study which demonstrated that TNF-α and IL-1β 
upregulate glucose transport in chondrocytes through upregulation of glucose transporter 
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(GLUT)1 and GLUT9 mRNA synthesis with increased levels of glycosylated GLUT1 
incorporated into the plasma membrane 76. This influx in glucose is likely, at least in part, 
to be due to the increased energy requirement following cytokine stimulation in the 
production of MMPs and secretion of IL-6, IL-8, hematopoietic colony-stimulating factor 
and prostaglandin E2 77. In addition, although glucose was not identified within the culture 
media, glycolysis and gluconeogenesis pathways were predicted to be upregulated based 
on numerous differentially abundant proteins within these pathways, including enolase 1. 
Enolase 1 is a multifunctional glycolytic enzyme which has previously been shown to have 
increased abundance within an equine articular cartilage model stimulated with IL-1β, as 
well as increased expression on the cell surface of immune cells during rheumatoid 
arthritis (RA) 68,78. Lee et al. identified apolipoprotein B within RA SF to be a specific ligand 
to enolase 1, provoking an inflammatory response. Elevated levels of apolipoprotein B 
have also been associated with human knee OA 79. Thus lipid metabolism may operate 
through this mechanism to regulate chronic inflammation in OA as well as RA 78. 
Within gluconeogenesis, the ten differentially abundant molecules identified within this 
pathway also included enolase 1, as well as alanine and choline. Across the whole study, 
alanine was found to be a central component in discriminating control and treatment 
groups. Alanine levels were depleted in treated cartilage extracts compared to controls 
and identified as an important component in discriminating control and treated cartilage 
samples. Reduced alanine levels were also identified in human OA cartilage using 
HRMAS NMR spectroscopy 50. Within culture media, alanine was depleted at all time 
points in treated samples and involvement of alanine degradation and biosynthesis 
pathways identified as significant. Alanine has previously been identified as a key 
component of the metabolic urinary OA profile of guinea pigs 80. A 1H NMR metabolomics 
study of equine SF also identified elevated levels of choline in OA 41. However, elevated 
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levels of alanine and citrate were also identified whilst these were found to be decreased 
within our study. 
Upregulation of molecular transport pathways were driven by numerous differentially 
expressed metabolites and proteins including alanine, citrate, arginine, choline, RhoC, 
COMP and MMP-3. Along with actin cytoskeleton regulation, Rho GTPases are also 
known to regulate vesicle movement through vesicle trafficking, with ROCK1 co-localising 
with vesicles and involved in microvesicle production 72,81,82. Extracellular vesicles are now 
known to play an important role within OA pathogenesis, with their structure and cargo a 
growing area within OA research 83,84. It would therefore be of interest to use the 
techniques used within this study, to interrogate the metabolite and protein cargo of 
extracellular vesicles within this early OA model. 
Within this study, arginine levels were initially identified as decreased following treatment 
at the earliest time point. A recent study of human plasma also identified arginine to be 
depleted in knee OA 85. The authors proposed this is due to an increased activity of the 
conversion of arginine to ornithine resulting in an imbalance between cartilage repair and 
degradation. This is supported by a recent learning and network approach of OA 
associated metabolites in which arginine and ornithine appeared in about 30% and 25% of 
the generated models studied 86. In addition to this, a reduction in arginine may be 
reflective of an increased production of nitric oxide (L-arginine being converted to NOH-
arginine and subsequently L-citrulline and nitric oxide) as identified in human OA cartilage 
87,88. 
The cytoplasm organisation pathway was identified as significantly altered at 0-2 days, 
driven partially by reduced alanine levels and increased levels of RhoC and vimentin. 
Vimentin is a multifunctional intermediate filament protein 89. Within chondrocytes it has 
been demonstrated that vimentin is likely to be involved in mechanotransduction 90. Our 
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results are supported by a previous study which identified elevated levels of cleaved 
vimentin within human OA cartilage with distortion of the vimentin network evident 91. 
Isoleucine was elevated within the media during the latter stages of the model. Elevated 
isoleucine levels have previously been reported within SF of a canine OA model and 
human OA serum 39,92. Borel et al. previously identified elevations of peaks within 1H 
HRMAS NMR spectra of OA cartilage which could be attributed to isoleucine 49. Thus the 
elevations seen in isoleucine may be reflective of cartilage collagen breakdown 92. 
However, within this study, although a higher abundance was recorded for isoleucine in 
treated compared to control cartilage, this did not reach statistical significance. 
Furthermore, elevations in glutamate were identified within culture media at 3-5 days, 
which may be resultant of the catabolism of collagenous proline through proline oxidase 93. 
Reduced levels of collagen type VI α 2 chain and collagen type X α 1 chain were identified 
at 3-5 and 6-8 days following cytokine treatment. This may reflect a reduction in collagen 
synthesis which has previously been identified within other collagen types following TNF-
α/IL-1β stimulation 22. Therefore these results provide evidence of a disruption in collagen 
homeostasis and suggest that collagens are being degraded within the model sooner than 
the 14-28 days previously reported within other ex-vivo cartilage OA models 94,95. 
Coagulation factor XIII A chain, fibromodulin and lamin A/C levels were all identified as 
being elevated within culture media following TNF-α/IL-1β treatment at the earliest time 
point; 0-2 days. All three of these proteins were also identified as involved in alterations to 
cellular movement pathways, which have been central to the biological changes within the 
earlier stages of this OA model. 
Coagulation factor XIII is a heterotetrameric protein complex which crosslinks fibrin 
polymers through covalent bonds 96. Coagulation factor XIII A chain immunostaining was 
previously found to be elevated within human articular knee cartilage following IL-1β 
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stimulation 97. Sanchez et al. identified increased expression of coagulation factor XIII A 
chain in osteoblasts within the sclerotic zone of OA subchondral bone 98. Clinically, 
remodelling of the subchondral bone is likely to be closely related to cartilage degradation 
99. Within hypertrophic chondrocytes, Nurminkaya et al. concluded that cell death and lysis 
were responsible for the externalisation of the protein (Nurminkaya et al., 1998). However, 
coagulation factor XIII A chain has also been identified within articular cartilage vesicles, 
although the underlying externalisation mechanism remains unknown 101. 
Fibromodulin is a small leucine-rich repeat proteoglycan which interacts with collagen 
fibrils and influences fibrillogenesis rate and fibril structure 102. Experimental mice which 
lack biglycan and fibromodulin have been shown to develop OA in multiple joints 103,104. 
Neopeptides generated from fibromodulin degradation have also been identified as 
potential markers of equine articular cartilage degradation 28. 
Within our study, higher levels of Lamin A/C (intermediate filament protein) were identified 
within treated media samples 105. Lamin A/C has also been identified as being upregulated 
in human OA cartilage and elevated levels have been implicated in dysregulation of 
chondrocyte autophagy in ageing and OA 106,107. Thus, our results support these studies, 
with chondrocyte autophagy targeting a potential novel therapeutic route. 
Due to an elevation in enzymatic activity and breakdown of cartilage during OA, potential 
biomarkers include ECM degradation fragments 108. PCA identified that the semi-tryptic 
peptide profiles generated from treated equine cartilage was less variable than that of the 
controls, demonstrating the TNF-α/IL-1β treatment is driving the semi-tryptic peptide profile 
within the model. Within this study we have identified several semi-tryptic peptides 
(potential neopeptides) which were identified as being elevated following treatment 
compared to controls, including degradation products from ECM proteins aggrecan, 
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cartilage intermediate layer protein, vimentin and collagen type VI. None of these potential 
neopeptides have previously been identified within the literature 28,33,34,68. 
Study Limitations 
Previously an in vivo study of equine OA identified physiological levels of TNF-α and IL-1β 
within SF to be 40-80 pg/ml 19. However our study, along with previous studies in the field, 
has used significantly higher cytokine concentrations to experimentally model OA 20–25. 
This approach was used within this study due to the short half-lives of these two cytokines 
109,110. Supplementation at a concentration closer to physiological levels would ultimately 
result in the experiment being largely conducted with cytokine levels significantly below 
that experienced during OA, thus producing results that may be of insufficient benefit. 
Therefore, the approach used within this study to model OA should be taken into 
consideration when interpreting the results. 
The cytokine preparations used within this study contained various metabolites which, 
following their removal from subsequent statistical analysis, prevented the analysis of 
some various metabolites within the experiment. Additionally, culture media was 
supplemented with a protease inhibitor cocktail at collection to inhibit general protein 
degradation prior to MS proteomic analysis, with results therefore representing the 
peptide/protein composition during experimentation. However, the high mannitol content 
prevented analysis of this metabolite within the samples/spectral region. Therefore, when 
in future using cytokines/supplements for NMR metabolomics, analysing the spectra of 
different manufacturers/preparations prior to experimentation may be beneficial to identify 
their associated metabolite profiles, selecting the most appropriate products to maximise 




Within this study, OA was modelled using a combined treatment of TNF-α and IL-1β. Now 
that a method has been optimised to extract metabolites from articular cartilage for 1H 
NMR analysis and protocols established to concurrently investigate metabolite and protein 
profiles within culture media, it may be of interest to subsequently explore the effect 
separate TNF-α and IL-1β treatments, comparing these results to those identified within 
this study. Additional MS based metabolomics analysis of the culture media within this 
study may be beneficial as NMR and MS are complementary techniques and would 
therefore expand the number of identified/quantified metabolites, additionally identifying 
potential lipid and carbohydrate profiles of interest 9,38,43,111. In order to confirm the 
differentially abundant proteins within this study, validation using an orthologous technique 
e.g. western blotting or enzyme-linked immunosorbent assays is required. Further 
validation of potential neopeptides could also be carried out through multiple reaction 
monitoring using a triple-quadrupole mass spectrometer 112. Following this, development of 
monoclonal antibodies specific to neopeptides of interest would enable simpler monitoring 
of neopeptide abundance in in vitro, ex-vivo and clinical environments 113. Following 
validations, monitoring the differentially abundant metabolites, proteins and neopeptides 
within this study within longitudinal SF samples from OA horses would identify translation 
of these findings to a clinical setting and the eventual generation of clinically applicable 
diagnostic tests.  
Conclusion 
In conclusion, this is the first study to use a multi ‘omics’ approach to simultaneously 
investigate the metabolomic profile of ex-vivo cartilage and metabolomic/proteomic profiles 
of culture media using the TNF-α/IL-1β ex-vivo OA cartilage model. We have identified a 
panel of metabolites and proteins which are differentially abundant within an early phase of 
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the OA model, 0-2 days, which may provide further information on the underlying disease 
pathogenesis as well as potential to translate to clinical markers. Altered pathways 
implicated within this model were largely dominated by those involved in cellular 
movement. This study has also identified a panel of potential, ECM derived, neopeptides 
which have potential to help enable OA stratification as well as provide potential novel 
therapeutic targets. 
Supporting Information 
Liquid Chromatography Tandem Mass Spectrometry - Detailed Methods 
Figure S1. Five post mortem equine metacarpophalangeal joints used for ex-vivo cartilage 
culture.  
Figure S2. Experimental design for ex-vivo equine cartilage culture +/- TNF-α/IL-1β 
treatment. MCP = metacarpophalangeal. 
Figure S3. 1D 1H nuclear magnetic resonance spectral quantile plots of cartilage - 8 days 
in control media, cartilage - 8 days in TNF-α/IL-1β treated media, control media (all time 
points combined) and TNF-α/IL-1β treated media (all time points combined). 
Figure S4. Representative culture media ion chromatograms of combined time points for 
control and TNF-α/IL-1β treated equine ex-vivo cartilage explants using a 60 min liquid 
chromatography gradient. 
Figure S5. Principal component analysis scores plot identifying high reproducibility of 
acetonitrile cartilage metabolite extraction (three separate equine donors, technical 
triplicate for each donor) using 1D 1H NMR metabolome analysis. 
Figure S6. PC1 RMS (Principal component 1 root mean square) values for the 25 
components with the highest magnitude for differentially abundant proteins present within 
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culture media at (A) 0-2 days, (B) 3-5 days and (C) 6-8 days following TNF-α/IL-1β 
treatment of ex-vivo equine cartilage. n=5 for each time point. RMS: High = high in 
treatment with respect to control, Low = low in treatment with respect to control. 
Figure S7. Silver stain identifying media protein profiles (combined for all time points) 
following incubation of ex-vivo equine cartilage for control and TNF-α/IL-1β treated 
samples.  
Figure S8. Principal component analyses of semi-tryptic peptide profiles within culture 
media of control and TNF-α/IL-1β treated ex-vivo equine cartilage at 0-2 days, 3-5 days 
and 6-8 days. 
Figure S9. Heat maps identifying canonical pathway groupings associated with diseases 
and biological functions altered for 0-2 days, 3-5 days and 6-8 days within culture media 
following TNF-α/IL-1β treatment of ex-vivo equine cartilage explants. 
Figure S10. Networks involved in cell movement, migration of cells and invasion of cells in 
culture media at 0-2 days following TNF-α/IL-1β treatment of ex-vivo equine cartilage 
explants. 
Table S1. All proteins identified within culture media, including control and TNF-α/IL-1β 
treated ex-vivo equine cartilage sample wells. 
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